**Correction to: Crit Care 24, 442 (2020)**
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Following publication of the original article \[[@CR1]\], the authors reported errors in Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}.

The revised Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"} are indicated hereafter. Table 1Patients demographic and clinical characteristicsAll (*n* = 200)Levosimendan (*n* = 53)Control (*n* = 147)*p* valueClinical characteristics at ICU admission Age (years)53 ± 13.553.9 ± 14.352.6 ± 13.30.575 Male129 (64.5)33 (62.3)96 (65.3)0.692 BMI (kg/m^2^)25.3 ± 5.425.3 ± 5.625.3 ± 5.30.975 SAPS-II52.2 ± 14.353.5 ± 10.851.7 ± 15.40.349 SOFA11.7 ± 2.111.5 ± 1.511.8 ± 2.20.459Comorbidities Hypertension62 (31)18 (34)44 (29.9)0.587 Diabetes36 (18)11 (20.8)25 (17)0.430 History of congestive heart failure101 (51)26 (50)75 (51.4)0.865 Coronary artery disease88 (44)27 (50.9)61 (41.5)0.235 Peripheral artery disease11 (5.5)4 (7.5)7 (4.8)0.446 History of stroke14 (7)5 (9.4)9 (6.1)0.418 Smoking71 (35.5)18 (34)53 (36.1)0.785 Dyslipidemia49 (24.5)14 (26.4)35 (23.8)0.705 Renal failure with dialysis15 (7.5)3 (5.6)12 (8.1)0.553Indication for VA-ECMO0.068 Post-cardiotomy59 (29.5)18 (34)41 (27.9) Acute myocardial infarction45 (22.5)17 (32.1)28 (19) Graft dysfunction33 (16.5)3 (5.7)30 (20.4) Dilated cardiomyopathy15 (7.5)5 (9.4)10 (6.8) Intoxication14 (7)0 (0)14 (9) Fulminant myocarditis13 (6.5)3 (5.7)10 (6.8) Pulmonary embolism6 (3)2 (3.8)4 (2.7) Septic cardiomyopathy6 (3)2 (3.8)4 (2.7) Others9 (4.5)3 (5.6)6 (4)Potential for myocardial recovery0.264 High39 (19.5)7 (13.2)32 (21.8) Intermediate86 (43)22 (41.5)64 (43.5) Low75 (37.5)24 (45.3)51 (34.7)Hemodynamic parameters at admission LVEF (%)19.6 ± 11.318 ± 11.120.2 ± 11.40.241 TAPSE \< 12 (mm)45 (30.8)15 (34.8)30 (29.1)0.489 MAP (mmHg)69 ± 1170 ± 1169 ± 110.643 HR (beats/min)103 ± 24108 ± 21102 ± 250.145 CVP (mmHg)10.6 ± 510.8 ± 5.510.6  ± 4.90.798 ScvO~2~ (%)62 ± 1160  ± 1263 ± 110.065VA-ECMO characteristics VA-ECMO duration (days)7.6 ± 510.6 ± 4.86.5  ±  4.7**\< 0.001** Flow rate (L/min)3.5 ± 0.83.4 ± 0.83.5 ± 0.80.835 Rotation (round/min)4360 ± 17114480 ± 17244312 ± 17100.547 FiO~2~ (%)59 ± 1258 ± 1259 ±  130.977 Peripheral VA-ECMO canulation175 (87.5)48 (90.6)127 (86.4)0.496 IABP associated to VA-ECMO54 (27)16 (30.1)38 (25.8)0.542Biological parameters Hemoglobin level (g/dL)113 ± 25114 ± 26113 ± 240.717 International normalized ratio1.6 ± 0.61.5 ± 0.51.6 ± 0.60.338 Arterial blood pH7.26 ±  ± 0.17.27 ± 0.17.26 ± 0.10.652 Lactate level (mmol/L)7.2 ± 5.16.4 ± 4.77.5 ± 5.30.178 Creatinine level (μmol/L)152 ± 78150 ± 77153 ± 790.843 Total bilirubin level (μmol/L)23 ± 1722 ± 1724 ± 170.457 ASAT (U/L)763 ± 1819717 ±  ±  1454781 ± 19450.828 ALAT (U/L)390 ± 907295 ± 610426 ± 9980.372Catecholamines during ICU stay Norepinephrine max dose (μg/kg/min)1.49 ± 1.051.56 ± 1.071.47 ± 1.040.586 Norepinephrine duration (days)10.9 ± 8.712.8 ± 7.210.2 ± 9.20.068 Dobutamine max dose (μg/kg/min)9.7 ± 4.610.4 ± 10.29.5 ± 4.30.309 Dobutamine duration (days)9.1 ± 7.910.3 ± 10.28.6 ± 6.60.203*ICU* intensive care unit, *BMI* body mass index, *SAPS-II* simplified acute physiology score, *SOFA* sequential organ failure assessment, *LVEF* left ventricular ejection fraction, *TAPSE* tricuspid annular plane systolic excursion, *MAP* mean arterial pressure, *HR* heart rate, *CVP* central venous pressure, *ScvO*~*2*~ central venous oxygen saturation, *FiO*~*2*~ fractional inspired oxygen, *IABP* intra-aortic balloon pump, *ASAT* aspartate aminotransferase, *ALAT* alanine aminotransferaseTable 2Balance of covariates before and after matchingUnmatched\*MatchedLevosimendan (*n* = 48)Control (*n* = 128)*p*Levosimendan (*n* = 48)Control (*n* = 78)*p***Variable (mean)** Age (years)53.952.60.57554.354.70.866 Male (%)62650.6920.620.650.785 Potential for recovery2.322.120.1042.312.350.747 SAPS-II53.551.70.42452.752.10.824 SOFA11.511.80.53011.311.50.687 LVEF (%)1820.20.24118170.690 VA-ECMO duration (days)10.66.5**\< 0.001**10.810.2**0.478** Serum lactate level (mmol/L)6.47.50.1786.36.10.816Myocardial recovery potential: *High 1* intermediate 2, *Low 3 SAPS-II* simplified acute physiology score, *SOFA* sequential organ failure assessment, *LVEF* left ventricular ejection fraction. Data are expressed as mean. The *p* value refers to a comparison between the levosimendan group and the control group. \*Compared to the entire cohort (*n* = 200), the unmatched population had 176 patients since there were 24 patients with missing data on some of the variables used in the analysis

The original article \[[@CR1]\] has been updated.
